- ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
- Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
- Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
- ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
- ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
- ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
- ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
- Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
- ELEVAI Labs, Inc. Expands International Distribution into Europe
- Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products
More ▼
Key statistics
On Friday, ELEVAI Labs Inc (ELAB:NAQ) closed at 0.6592, 15.46% above the 52 week low of 0.5709 set on Apr 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.6799 |
---|---|
High | 0.6799 |
Low | 0.622 |
Bid | 0.64 |
Offer | 0.67 |
Previous close | 0.674 |
Average volume | 75.56k |
---|---|
Shares outstanding | 17.33m |
Free float | 3.09m |
P/E (TTM) | -- |
Market cap | 11.42m USD |
EPS (TTM) | -0.2482 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 20:59 BST.
More ▼